Would you favor an adjuvant anti-PD-1 inhibitor or dabrafenib/trametinib for stage IIIC/D resected BRAF V600K-mutated cutaneous melanoma?

There are no good, randomized controlled trials in the adjuvant setting for melanoma to answer this question conclusively. But extrapolating from the data in the metastatic setting, where it is quite clear that the "immunotherapy first" approach affords a benefit over the targeted therapy first appr...